Suchergebnisse - "Ullmann, Martin"

PubPharm (30)

1

2023 White Paper on Recent Issues in Bioanalysis : ISR for ADA Assays, the Rise of dPCR vs qPCR, International Reference Standards for Vaccine Assays, Anti-AAV TAb Post-Dose Assessment, NanoString Validation, ELISpot as Gold Standard

enthalten in: Bioanalysis | 2024

von Mora, J. | Palmer, R. | Wagner, L. | +55

2

Comparison of the efficacy and safety of a proposed biosimilar MSB11456 with tocilizumab reference product in subjects with moderate-to-severe rheumatoid arthritis : results of a randomised double-blind study

enthalten in: RMD open | 2024

von Zubrzycka-Sienkiewicz, A. | Klama, K. | Ullmann, M. | +4

3

Pharmacokinetics of a proposed tocilizumab biosimilar (MSB11456) versus US-licensed tocilizumab : results of a randomized, double-blind, single-intravenous dose study in healthy adults

enthalten in: Expert review of clinical immunology | 2023

von Tomaszewska-Kiecana, M. | Ullmann, M. | Petit-Frere, C. | +3

4

Pharmacokinetics and tolerability of prefilled syringe and auto-injector presentations of MSB11456 : results of a randomized, single-dose study in healthy adults

enthalten in: Expert review of clinical immunology | 2023

von Tomaszewska-Kiecana, M. | Dryja, A. | Ullmann, M. | +4

5

Pharmacokinetics and pharmacodynamics of a proposed tocilizumab biosimilar MSB11456 versus both the US-licensed and EU-approved products : a randomized, double-blind trial

enthalten in: Expert review of clinical immunology | 2022

von Schwabe, C. | Illes, A. | Ullmann, M. | +6

6

When to Extend Monitoring of Anti-drug Antibodies for High-risk Biotherapeutics in Clinical Trials : an Opinion from the European Immunogenicity Platform

enthalten in: The AAPS journal | 2022

von Lotz, G. | Benstein, K. | Bloem, K. | +19

7

When to Extend Monitoring of Anti-drug Antibodies for High-risk Biotherapeutics in Clinical Trials: an Opinion from the European Immunogenicity Platform

enthalten in: The AAPS journal | 2022

von Lotz, G. | Benstein, K. | Bloem, K. | +19

8

When to Extend Monitoring of Anti-drug Antibodies for High-risk Biotherapeutics in Clinical Trials: an Opinion from the European Immunogenicity Platform

enthalten in: AAPS PharmSci | 2022

von Lotz, G. | Benstein, K. | Bloem, K. | +19

9

Pharmacokinetics and Pharmacodynamics of a Proposed Pegfilgrastim Biosimilar MSB11455 Versus the Reference Pegfilgrastim Neulasta in Healthy Subjects : A Randomized, Double-blind Trial

enthalten in: Clinical therapeutics | 2020

von Lickliter, J. | Kanceva, R. | Vincent, E. | +7

10

Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta® in healthy subjects : A randomized, double-blind trial

enthalten in: Pharmacology research & perspectives | 2020

von Wynne, C. | Schwabe, C. | Vincent, E. | +6